In addition to Canaccord Genuity, Dexcom also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on the same day, Barclays reiterated a Sell rating on Dexcom (NASDAQ: ...

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

The S&P 500 and Dow hit record highs Monday, with tech and Walmart shares climbing despite a Justice Department probe into ...

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.16%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.17%, ...

Shares rose 6.4% to $71.73, putting the stock on pace for its highest close since September, according to Dow Jones Market ...

(Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total ...

Bernstein analyst Lee Hambright maintained a Buy rating on Dexcom today and set a price target of $86.00. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and ...

Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.

DexCom, Inc. , the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership of President and CEO Jake Leach, who assumed his ...

Jan 6 (Reuters) - The U.S. Food and Drug Administration said on Tuesday that it will limit regulation of wearable devices ...